D.E. Shaw & Co
TEVA icon

D.E. Shaw & Co’s Teva Pharmaceuticals TEVA Stock Holding History

D.E. Shaw & Co’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.22M Sell
140,073
-507,038
-78% -$16.3M ﹤0.01% 2301
2025
Q4 		$20.2M Buy
647,111
+477,944
+283% +$11.8M 0.01% 1231
2025
Q3 		$3.42M Buy
169,167
+47,346
+39% +$832K ﹤0.01% 2542
2025
Q2 		$2.04M Buy
121,821
+40,637
+50% +$656K ﹤0.01% 2729
2025
Q1 		$1.25M Sell
81,184
-2,427,905
-97% -$43.4M ﹤0.01% 2945
2024
Q4 		$55.3M Sell
2,509,089
-1,145,369
-31% -$20.8M 0.04% 536
2024
Q3 		$65.9M Sell
3,654,458
-2,230,589
-38% -$39M 0.06% 406
2024
Q2 		$95.6M Buy
5,885,047
+3,966,146
+207% +$61.1M 0.09% 267
2024
Q1 		$27.1M Buy
1,918,901
+404,319
+27% +$5.1M 0.02% 758
2023
Q4 		$15.8M Sell
1,514,582
-4,524,093
-75% -$42.2M 0.01% 1072
2023
Q3 		$61.6M Buy
6,038,675
+582,945
+11% +$5.43M 0.06% 361
2023
Q2 		$41.1M Buy
5,455,730
+4,039,979
+285% +$32.8M 0.04% 508
2023
Q1 		$12.5M Sell
1,415,751
-803,544
-36% -$7.95M 0.01% 1197
2022
Q4 		$20.2M Sell
2,219,295
-1,725,040
-44% -$15.1M 0.02% 912
2022
Q3 		$31.8M Buy
3,944,335
+2,631,829
+201% +$23.3M 0.04% 603
2022
Q2 		$9.87M Sell
1,312,506
-2,314,089
-64% -$20.2M 0.01% 1400
2022
Q1 		$34.1M Buy
3,626,595
+1,455,442
+67% +$12.1M 0.03% 679
2021
Q4 		$17.4M Sell
2,171,153
-527,500
-20% -$4.76M 0.01% 1195
2021
Q3 		$26.3M Buy
2,698,653
+2,595,704
+2,521% +$24.3M 0.02% 855
2021
Q2 		$1.02M Buy
102,949
+28,156
+38% +$298K ﹤0.01% 3518
2021
Q1 		$863K Sell
74,793
-608,800
-89% -$6.98M ﹤0.01% 3218
2020
Q4 		$6.6M Buy
683,593
+371,640
+119% +$3.56M 0.01% 1664
2020
Q3 		$2.81M Buy
311,953
+148,339
+91% +$1.57M ﹤0.01% 2133
2020
Q2 		$2.02M Sell
163,614
-248,018
-60% -$2.8M ﹤0.01% 2404
2020
Q1 		$3.7M Buy
411,632
+11,864
+3% +$122K 0.01% 1691
2019
Q4 		$3.92M Sell
399,768
-2,080,991
-84% -$18.6M ﹤0.01% 1921
2019
Q3 		$17.1M Sell
2,480,759
-396,778
-14% -$3.04M 0.02% 847
2019
Q2 		$26.6M Buy
2,877,537
+2,671,960
+1,300% +$32.2M 0.03% 616
2019
Q1 		$3.22M Sell
205,577
-440,775
-68% -$7.77M ﹤0.01% 1833
2018
Q4 		$9.97M Buy
646,352
+267,623
+71% +$5.49M 0.01% 1095
2018
Q3 		$8.16M Buy
378,729
+119,592
+46% +$2.78M 0.01% 1233
2018
Q2 		$6.3M Sell
259,137
-1,005,699
-80% -$20.5M 0.01% 1365
2018
Q1 		$21.6M Sell
1,264,836
-213,136
-14% -$4.16M 0.03% 626
2017
Q4 		$28M Sell
1,477,972
-29,534
-2% -$444K 0.04% 533
2017
Q3 		$26.5M Buy
1,507,506
+946,515
+169% +$21.3M 0.04% 509
2017
Q2 		$18.6M Sell
560,991
-972,644
-63% -$30.1M 0.03% 613
2017
Q1 		$49.2M Sell
1,533,635
-858,414
-36% -$29.3M 0.09% 290
2016
Q4 		$86.7M Sell
2,392,049
-2,398,817
-50% -$95.8M 0.15% 151
2016
Q3 		$220M Buy
4,790,866
+52,809
+1% +$2.76M 0.39% 35
2016
Q2 		$238M Sell
4,738,057
-1,063,206
-18% -$56.6M 0.44% 30
2016
Q1 		$310M Buy
5,801,263
+1,790,797
+45% +$105M 0.56% 21
2015
Q4 		$263M Sell
4,010,466
-419,580
-9% -$25.9M 0.39% 41
2015
Q3 		$250M Buy
4,430,046
+1,187,593
+37% +$77M 0.37% 42
2015
Q2 		$192M Buy
3,242,453
+1,530,292
+89% +$94.4M 0.29% 57
2015
Q1 		$107M Buy
1,712,161
+382,351
+29% +$22.2M 0.16% 135
2014
Q4 		$76.5M Sell
1,329,810
-1,629,232
-55% -$90.8M 0.1% 240
2014
Q3 		$159M Buy
2,959,042
+510,403
+21% +$27M 0.21% 87
2014
Q2 		$128M Buy
2,448,639
+846,764
+53% +$43.3M 0.17% 109
2014
Q1 		$84.6M Buy
1,601,875
+1,096,366
+217% +$50.7M 0.12% 175
2013
Q4 		$20.3M Sell
505,509
-1,072,077
-68% -$42.2M 0.03% 683
2013
Q3 		$59.6M Buy
1,577,586
+605,725
+62% +$23.6M 0.1% 214
2013
Q2 		$38.1M Buy
+971,861
New +$37.8M 0.07% 298

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co's TEVA Position: Q1 2026 in Review

D.E. Shaw & Co reduced its Teva Pharmaceuticals (TEVA) stake by 78% in Q1 2026, selling an estimated $16.3M and leaving 140,073 shares worth $4.22M. The position accounts for ﹤0.01% of the portfolio, ranked #2301.

D.E. Shaw & Co first reported a position in TEVA in Q2 2013 and has held it in 52 quarters since. The position peaked at $310M in Q1 2016. 650 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

  • D.E. Shaw & Co held 140,073 shares of Teva Pharmaceuticals worth $4.22M as of Q1 2026.
  • D.E. Shaw & Co sold 507,038 Teva Pharmaceuticals shares in Q1 2026, an estimated $16.3M.
  • Teva Pharmaceuticals made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #2301 holding.
  • D.E. Shaw & Co first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • D.E. Shaw & Co's Teva Pharmaceuticals position peaked at $310M in Q1 2016.
  • 650 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.